West Pharmaceutical Services, Inc. $WST Stock Position Lessened by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC trimmed its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 51.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 8,494 shares of the medical instruments supplier’s stock after selling 8,878 shares during the period. Motley Fool Asset Management LLC’s holdings in West Pharmaceutical Services were worth $3,149,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in WST. Hanseatic Management Services Inc. bought a new position in shares of West Pharmaceutical Services during the third quarter valued at about $605,000. VestGen Advisors LLC purchased a new stake in shares of West Pharmaceutical Services during the third quarter worth about $235,000. Generali Asset Management SPA SGR grew its stake in shares of West Pharmaceutical Services by 10.4% in the third quarter. Generali Asset Management SPA SGR now owns 2,948 shares of the medical instruments supplier’s stock worth $1,093,000 after purchasing an additional 277 shares during the last quarter. Oppenheimer & Co. Inc. grew its stake in shares of West Pharmaceutical Services by 9.8% in the third quarter. Oppenheimer & Co. Inc. now owns 4,969 shares of the medical instruments supplier’s stock worth $1,842,000 after purchasing an additional 443 shares during the last quarter. Finally, Signaturefd LLC increased its holdings in West Pharmaceutical Services by 26.9% during the 3rd quarter. Signaturefd LLC now owns 1,194 shares of the medical instruments supplier’s stock valued at $443,000 after purchasing an additional 253 shares during the period. 93.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. BNP Paribas Exane began coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price target for the company. Evercore reiterated an “outperform” rating and issued a $425.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, July 27th. TD Cowen lifted their price objective on West Pharmaceutical Services from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. Citigroup boosted their target price on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Finally, Weiss Ratings upgraded West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $391.17.

Trending Headlines about West Pharmaceutical Services

Here are the key news stories impacting West Pharmaceutical Services this week:

• Positive Sentiment: West reported third-quarter sales of $874.5 million, up 8.7% year over year and well above the $827.1 million analyst consensus. Adjusted diluted EPS was $2.66, compared with expectations of approximately $2.18-$2.20 and $1.96 in the prior-year quarter. West Reports Third-Quarter 2026 Results
• Positive Sentiment: The company raised its full-year 2026 net-sales guidance to $3.41 billion-$3.42 billion, from $3.345 billion-$3.380 billion previously. Adjusted diluted EPS guidance increased to $9.38-$9.48, versus the prior range of $8.85-$9.05. West Pharmaceutical Services Raises Annual Outlook
• Positive Sentiment: High-Value Product Components sales rose 19.7% and represented 53% of quarterly revenue. The mix shift supported margin expansion and reinforced investor confidence in demand for West’s specialized injectable and pharmaceutical packaging components. West Pharma Q3 Earnings Rise on HVP Strength
• Neutral Sentiment: Management’s earnings-call commentary emphasized continued operating execution and portfolio strength, while the outlook implies further growth but also leaves the stock dependent on sustained demand and margin performance. West Pharmaceutical Services Q3 2026 Earnings Call Transcript
• Negative Sentiment: Valuation remains a potential constraint: WST trades at a high earnings multiple, while a recent analysis argued that cash flow does not fully support the current valuation. In addition, reported insider activity showed selling without purchases during the past six months. West Stock Could Be Overvalued

Insider Buying and Selling at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Annette Favorite sold 8,135 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $340.81, for a total transaction of $2,772,489.35. Following the transaction, the vice president owned 16,845 shares in the company, valued at approximately $5,740,944.45. This represents a 32.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 15,659 shares of company stock worth $5,443,749. 0.60% of the stock is currently owned by corporate insiders.

West Pharmaceutical Services Trading Up 3.2%

NYSE:WST opened at $416.55 on Friday. The company has a 50-day moving average price of $366.60 and a 200-day moving average price of $312.50. The stock has a market cap of $29.32 billion, a price-to-earnings ratio of 53.34, a P/E/G ratio of 2.83 and a beta of 1.13. The company has a current ratio of 2.82, a quick ratio of 2.12 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $223.83 and a 12 month high of $438.27.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 29th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.20 by $0.46. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The company had revenue of $874.50 million for the quarter, compared to analysts’ expectations of $827.12 million. During the same quarter in the previous year, the company earned $1.96 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 8.7% on a year-over-year basis. Equities analysts predict that West Pharmaceutical Services, Inc. will post 8.92 EPS for the current year.

West Pharmaceutical Services Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 18th. Shareholders of record on Wednesday, November 11th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Tuesday, November 10th. This is a positive change from West Pharmaceutical Services’s previous quarterly dividend of $0.22. West Pharmaceutical Services’s payout ratio is presently 11.27%.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc develops and manufactures components and delivery systems used in the administration and packaging of injectable medicines and other healthcare products. Its offerings include elastomer closures, seals, syringe components, drug-delivery systems, and other specialized packaging components designed to support the safety, quality, and performance of pharmaceutical products.

The company also provides contract-manufacturing services for pharmaceutical, biotechnology, and medical-device customers.